A citation-based method for searching scientific literature

Miriam Molina-Arcas, Christopher Moore, Sareena Rana, Febe van Maldegem, Edurne Mugarza, Pablo Romero-Clavijo, Eleanor Herbert, Stuart Horswell, Lian-Sheng Li, Matthew R Janes, David C Hancock, Julian Downward. Sci Transl Med 2019
Times Cited: 64







List of co-cited articles
871 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
537
75

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
316
73

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
408
60

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
939
60

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
326
48

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Sandra Misale, Jackson P Fatherree, Eliane Cortez, Chendi Li, Samantha Bilton, Daria Timonina, David T Myers, Dana Lee, Maria Gomez-Caraballo, Max Greenberg,[...]. Clin Cancer Res 2019
80
45

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Piro Lito, Martha Solomon, Lian-Sheng Li, Rasmus Hansen, Neal Rosen. Science 2016
299
39

Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
929
39

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Jenny Y Xue, Yulei Zhao, Jordan Aronowitz, Trang T Mai, Alberto Vides, Besnik Qeriqi, Dongsung Kim, Chuanchuan Li, Elisa de Stanchina, Linas Mazutis,[...]. Nature 2020
111
39

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.
Meagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, David T Myers, Edmond Wong, Heather A Shahzade, Catriona B Hong, Ryan B Corcoran. Clin Cancer Res 2020
86
37

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
290
35

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.
Kevin Lou, Veronica Steri, Alex Y Ge, Y Christina Hwang, Christopher H Yogodzinski, Arielle R Shkedi, Alex L M Choi, Dominique C Mitchell, Danielle L Swaney, Byron Hann,[...]. Sci Signal 2019
53
41

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Roman C Hillig, Brice Sautier, Jens Schroeder, Dieter Moosmayer, André Hilpmann, Christian M Stegmann, Nicolas D Werbeck, Hans Briem, Ulf Boemer, Joerg Weiske,[...]. Proc Natl Acad Sci U S A 2019
105
31

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
187
29

RAS Proteins and Their Regulators in Human Disease.
Dhirendra K Simanshu, Dwight V Nissley, Frank McCormick. Cell 2017
552
29

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, Christopher J Schulze, Golzar Hemmati, David Wildes, Christos Tzitzilonis, Kasia Mordec, Abby Marquez, Jason Romero,[...]. Nat Cell Biol 2018
128
25

A combinatorial strategy for treating KRAS-mutant lung cancer.
Eusebio Manchado, Susann Weissmueller, John P Morris, Chi-Chao Chen, Ramona Wullenkord, Amaia Lujambio, Elisa de Stanchina, John T Poirier, Justin F Gainor, Ryan B Corcoran,[...]. Nature 2016
226
25

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey D Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro,[...]. Nat Med 2018
132
23

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Dietrich A Ruess, Guus J Heynen, Katrin J Ciecielski, Jiaoyu Ai, Alexandra Berninger, Derya Kabacaoglu, Kivanc Görgülü, Zahra Dantes, Sonja M Wörmann, Kalliope N Diakopoulos,[...]. Nat Med 2018
152
23

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
John C Hunter, Anuj Manandhar, Martin A Carrasco, Deepak Gurbani, Sudershan Gondi, Kenneth D Westover. Mol Cancer Res 2015
225
23

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Carmine Fedele, Hao Ran, Brian Diskin, Wei Wei, Jayu Jen, Mitchell J Geer, Kiyomi Araki, Ugur Ozerdem, Diane M Simeone, George Miller,[...]. Cancer Discov 2018
106
21

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Matthew A Coelho, Sophie de Carné Trécesson, Sareena Rana, Davide Zecchin, Christopher Moore, Miriam Molina-Arcas, Philip East, Bradley Spencer-Dene, Emma Nye, Karin Barnouin,[...]. Immunity 2017
245
21

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
552
21

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
G R Blumenschein, E F Smit, D Planchard, D-W Kim, J Cadranel, T De Pas, F Dunphy, K Udud, M-J Ahn, N H Hanna,[...]. Ann Oncol 2015
187
21

RAS-targeted therapies: is the undruggable drugged?
Amanda R Moore, Scott C Rosenberg, Frank McCormick, Shiva Malek. Nat Rev Drug Discov 2020
140
21

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Vito Amodio, Rona Yaeger, Pamela Arcella, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato, Sabrina Arena, Monica Montone, Benedetta Mussolin, Yu Bian,[...]. Cancer Discov 2020
62
22

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.
Anurag Singh, Patricia Greninger, Daniel Rhodes, Louise Koopman, Sheila Violette, Nabeel Bardeesy, Jeff Settleman. Cancer Cell 2009
560
20

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Gabrielle S Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E Schumacher, Jens Puschhof, James McFarland,[...]. Nat Med 2018
109
20

Drugging an undruggable pocket on KRAS.
Dirk Kessler, Michael Gmachl, Andreas Mantoulidis, Laetitia J Martin, Andreas Zoephel, Moriz Mayer, Andreas Gollner, David Covini, Silke Fischer, Thomas Gerstberger,[...]. Proc Natl Acad Sci U S A 2019
117
20

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
Kirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, Jennifer E Klomp, Sen Peng, Andrey P Tikunov, Venugopal Gunda, Mariaelena Pierobon, Andrew M Waters, Samuel D George,[...]. Nat Med 2019
239
20

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Conan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, Katrin P Guillen, Mona Foth, Amanda Truong, Sophia S Schuman, Jill E Shea, Michael T Seipp, Jeffrey T Yap,[...]. Nat Med 2019
238
20

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, Fabio Savarese, Daniel Gerlach, Joseph R Marszalek, Michael P Sanderson, Dirk Kessler, Francesca Trapani, Heribert Arnhof,[...]. Cancer Discov 2021
53
24

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
Chong Sun, Sebastijan Hobor, Andrea Bertotti, Davide Zecchin, Sidong Huang, Francesco Galimi, Francesca Cottino, Anirudh Prahallad, Wipawadee Grernrum, Anna Tzani,[...]. Cell Rep 2014
202
17

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
Miriam Molina-Arcas, David C Hancock, Clare Sheridan, Madhu S Kumar, Julian Downward. Cancer Discov 2013
117
17

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
17

A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
17

The Frequency of Ras Mutations in Cancer.
Ian A Prior, Fiona E Hood, James L Hartley. Cancer Res 2020
110
17

RAS isoforms and mutations in cancer at a glance.
G Aaron Hobbs, Channing J Der, Kent L Rossman. J Cell Sci 2016
343
15

RAS oncogenes: weaving a tumorigenic web.
Yuliya Pylayeva-Gupta, Elda Grabocka, Dafna Bar-Sagi. Nat Rev Cancer 2011
15

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
319
15


Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
412
15

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Ernest Nadal, Guoan Chen, John R Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P Kalemkerian, Dean Brenner, Jules Lin, Rishindra M Reddy,[...]. J Thorac Oncol 2014
66
14

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikos I Poulikakos, Chao Zhang, Gideon Bollag, Kevan M Shokat, Neal Rosen. Nature 2010
14

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Hidenori Kitai, Hiromichi Ebi, Shuta Tomida, Konstantinos V Floros, Hiroshi Kotani, Yuta Adachi, Satoshi Oizumi, Masaharu Nishimura, Anthony C Faber, Seiji Yano. Cancer Discov 2016
79
14

Therapeutic strategies to target RAS-mutant cancers.
Meagan B Ryan, Ryan B Corcoran. Nat Rev Clin Oncol 2018
102
14

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Alexandria P Cogdill, Ronald D Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E Hung,[...]. Cancer Discov 2012
603
14

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Sang Min Lim, Kenneth D Westover, Scott B Ficarro, Rane A Harrison, Hwan Geun Choi, Michael E Pacold, Martin Carrasco, John Hunter, Nam Doo Kim, Ting Xie,[...]. Angew Chem Int Ed Engl 2014
203
14

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
138
14

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Nan Chen, Wenfeng Fang, Zhong Lin, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Jin Sheng,[...]. Cancer Immunol Immunother 2017
111
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.